{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.0","upperLimit":"35.5","value":"28.3"},{"groupId":"OG001","lowerLimit":"25.4","upperLimit":"33.1","value":"29.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"557"},{"groupId":"OG001","value":"553"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Participants who had not died were censored at the date of the last adequate tumor assessment at the time of the cut-off.","reportingStatus":"POSTED","timeFrame":"From randomization until date of death from any cause, assessed up to approximately 62 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}